Fundraising FoxMDI Therapeutics
Novi, US · Founded 2015 · Michigan corporation
Find your way into MDI Therapeutics
107 people in our graph can introduce you to the MDI Therapeutics team.
Sign up to see every warm intro you have to MDI Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the MDI Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MDI Therapeutics is a pharmaceutical company developing small molecule therapies for fibrosis and fibroproliferative diseases, including MDI-2517, an inhibitor of plasminogen activator inhibitor 1 (PAI-1) currently in a Phase 1 clinical study. It operates in the biotech and drug development space.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$1.7M disclosed across 1 of 2 rounds · 2018–2022
▶$1.7MraisedMar 2022 · 3 investors · BiotechnologyRule 506(b)
- Stephen C BenoitExecutive Officer, Director
- Duane E DayExecutive Officer
- Grazia PiizziDirector
- Daniel A LawrenceExecutive Officer
- David GinsburgDirector
- Offering amount
- $9.7M
- Amount sold
- $1.7M
- First sale
- Feb 2022
- Incorporated
- Corporation, Michigan, 2022
- Federal exemptions
- 06b
▶$1.6MofferedFeb 2018 · PharmaceuticalsRule 506(b)
- Daniel Lawrence, Ph.D.Executive Officer, Director
- Duane DayExecutive Officer, Director
- Stephen BenoitExecutive Officer, Director
- Offering amount
- $1.6M
- Minimum investment
- $250K
- Incorporated
- Corporation, Michigan, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as MDI Therapeutics.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $216.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does MDI Therapeutics do?
- MDI Therapeutics is a pharmaceutical company developing small molecule therapies for fibrosis and fibroproliferative diseases, including MDI-2517, an inhibitor of plasminogen activator inhibitor 1 (PAI-1) currently in a Phase 1 clinical study. It operates in the biotech and drug development space.
- How much funding has MDI Therapeutics raised?
- MDI Therapeutics has disclosed $1.7M raised across 1 of its 2 known rounds.
- Where is MDI Therapeutics headquartered?
- MDI Therapeutics is headquartered in Novi, US.